Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2023-01-17 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于股东减持股份预披露的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement by a shareholder of a company regarding a planned reduction in their shareholding. It details the shareholder's current holdings, the planned amount and method of share reduction, timing, and compliance with relevant regulations. There are no financial statements, earnings data, or management discussion of results. The document is a notification of a shareholder's intention to reduce shares, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a full report or announcement of a meeting or dividend.
2023-01-17 Chinese
中信证券股份有限公司关于贝达药业股份有限公司2023年日常关联交易预计事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities Co., Ltd. as the sponsor institution for Betta Pharmaceuticals Co., Ltd. It provides a specialized verification opinion on the company's expected daily related-party transactions for the year 2023. The content includes detailed descriptions of related parties, transaction categories, amounts, pricing principles, and independent directors' opinions. It also includes financial data of related parties and compliance with regulatory rules. The document is lengthy (over 11,000 characters) and contains substantive financial and operational data related to related-party transactions, not merely an announcement or certification. It is not an annual report, earnings release, or management discussion but a specialized audit or verification report on related-party transactions. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report focusing on compliance and verification of related-party transactions, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2023
2023-01-17 Chinese
关于深圳证券交易所同意公司撤回向特定对象发行股票申请文件的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from a company regarding the withdrawal of its application to issue shares to specific investors. It references the termination of a stock issuance process and the regulatory approval to end the review. The text is short (739 characters) and focuses on the announcement of a capital market action rather than detailed financial data or a report. This fits the category of a Capital/Financing Update (CAP), as it relates to the company's financing activities and capital structure changes.
2023-01-13 Chinese
关于BPI-472372片药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about the acceptance of a clinical trial application by the National Medical Products Administration (NMPA). It details the clinical trial application status, drug information, and potential impact on the company. The document is short (1020 characters) and serves as an official announcement rather than a detailed report or financial filing. It does not contain financial data, management discussion, or regulatory certifications. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-13 Chinese
关于BPB-101双抗注射液药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the acceptance of a clinical trial application for a new drug (BPB-101) by the National Medical Products Administration (NMPA). It contains no financial data, no detailed financial statements, nor any management discussion of financial results. The document is short (1319 characters) and serves as a regulatory announcement about a clinical trial application acceptance, including risk warnings and impact statements. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any financial report. It is an official regulatory announcement about a clinical trial application acceptance, which aligns best with Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-01-13 Chinese
中信证券股份有限公司关于贝达药业股份有限公司与特定对象签署附条件生效的向特定对象发行股票认购协议之解除协议暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from CITIC Securities regarding the termination of a conditional stock subscription agreement between Betta Pharmaceuticals and a specific related party, Mr. Ding Lieming, who is the actual controller of the company. It discusses the background, approval process, independent director opinions, board and supervisory committee resolutions, and the impact of terminating the stock issuance. The document is regulatory in nature, related to a specific transaction and its cancellation, and includes compliance with listing rules and governance procedures. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, presentation, or remuneration report. It is not a full annual or interim report but a regulatory announcement about a transaction and related approvals. The document length is 4179 characters, which is relatively short and focused on a specific corporate action. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.